JAMA Author Interviews: Covering research in medicine, science,& clinical practice. For physicians, researchers,& clinicians.   /     Evaluating Treatments for Amyotrophic Lateral Sclerosis

Description

The HEALEY ALS platform is an innovative first attempt at platform trials in ALS, looking to slow ALS disease progression. Author Sabrina Paganoni, MD, PhD, of Massachusetts General Hospital and Harvard Medical School, discusses results of the first 4 drug regimens from this platform trial and how this study design makes efficient use of resources, with JAMA Deputy Editor Christopher Muth, MD. Related Content: Platform Clinical Trials for the Efficient Evaluation of Multiple Treatments Pridopidine in Amyotrophic Lateral Sclerosis Platform Trials in ALS Verdiperstat in Amyotrophic Lateral Sclerosis Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis CNM-Au8 in Amyotrophic Lateral Sclerosis

Subtitle
The HEALEY ALS platform is an innovative first attempt at platform trials in ALS, looking to slow ALS disease progression. Author Sabrina Paganoni, MD, PhD, of Massachusetts General Hospital and Harvard Medical School, discusses results of the first 4...
Duration
22:34
Publishing date
2025-02-17 16:00
Link
https://edhub.ama-assn.org/jn-learning/audio-player/10.1001/jama.2025.1084
Contributors
Enclosures
https://traffic.libsyn.com/secure/jamaauthorinterviews/Evaluating_Treatments_for_Amyotrophic_Lateral_Sclerosis.mp3?dest-id=90171
audio/mpeg

Shownotes

The HEALEY ALS platform is an innovative first attempt at platform trials in ALS, looking to slow ALS disease progression. Author Sabrina Paganoni, MD, PhD, of Massachusetts General Hospital and Harvard Medical School, discusses results of the first 4 drug regimens from this platform trial and how this study design makes efficient use of resources, with JAMA Deputy Editor Christopher Muth, MD. Related Content: